Skip to main content
SpringerLink
Log in

Androgen Deprivation Therapy Cardiotoxicity

  • Chapter
  • First Online:
Clinical Cases in Cardio-Oncology

Part of the book series: Clinical Cases in Cardiology ((CCC))

  • 316 Accesses

Abstract

The patient is a 63-year-old male, case of metastatic castrate-sensitive prostate cancer on goserelin injections every 3 month. Given his initial Gleason1 grade of 8, as well as doubling Prostate-specific antigen, (PSA) in 7 months since starting treatment, he was started on androgen receptor inhibitor, apalutamide. 2 weeks after starting treatment with apalutamide, patient presented with chest pain and shortness of breath. Follow up echocardiogram showed LVEF: 46%. Coronary angiogram showed moderate diffuse coronary artery disease but no significant obstruction. He was provided with betablocker, aspirin, and ramipril.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol. 1994;18(8):796–803.

    Article  CAS  Google Scholar 

  2. Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645–53.

    Article  Google Scholar 

  3. Higano CS. Cardiovascular disease and androgen axis-targeted drugs for prostate cancer. N Engl J Med. 2020;382(23):2257–9.

    Article  CAS  Google Scholar 

  4. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.

    Article  CAS  Google Scholar 

  5. Schmitt CA. Urological cancer: heart facts rehabilitate ADT. Nat Rev Clin Oncol. 2012;9(2):68.

    Article  Google Scholar 

  6. Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010;11(5):450–8.

    Article  Google Scholar 

  7. Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118(13):3397–406.

    Article  CAS  Google Scholar 

  8. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335–46.

    Article  Google Scholar 

  9. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer [published correction appears in J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23]. J Natl Cancer Inst. 2010;102(1):39–46. https://doi.org/10.1093/jnci/djp404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–500. https://doi.org/10.1002/cncr.22933.

    Article  CAS  PubMed  Google Scholar 

  11. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern Ontario School of Medicine, Thunder Bay, ON, Canada

    Atooshe Rohani

Authors
  1. Atooshe Rohani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atooshe Rohani .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rohani, A. (2021). Androgen Deprivation Therapy Cardiotoxicity. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71155-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71154-2

  • Online ISBN: 978-3-030-71155-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation